$4.47 Billion is the total value of DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s 122 reported holdings in Q1 2022. The portfolio turnover from Q4 2021 to Q1 2022 was 55.6% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| VTRS | Sell | VIATRIS INC | $224,930,000 | -20.0% | 20,673,700 | -0.5% | 5.03% | -14.7% |
| CMAX | Sell | CAREMAX INC | $121,813,000 | -5.5% | 15,861,090 | -5.5% | 2.72% | +0.7% |
| CNC | Sell | CENTENE CORP DEL | $46,624,000 | -43.6% | 553,800 | -44.8% | 1.04% | -39.9% |
| Sell | SEMA4 HOLDINGS CORP | $42,515,000 | -31.7% | 13,848,488 | -0.8% | 0.95% | -27.3% | |
| OMIC | Sell | SINGULAR GENOMICS SYSTEMS IN | $41,722,000 | -60.4% | 6,612,019 | -27.4% | 0.93% | -57.8% |
| PHVS | Sell | PHARVARIS N V | $28,600,000 | +25.7% | 1,577,078 | -0.3% | 0.64% | +34.0% |
| GKOS | Sell | GLAUKOS CORP | $21,365,000 | -58.6% | 369,514 | -68.2% | 0.48% | -55.9% |
| DAWN | Sell | DAY ONE BIOPHARMACEUTICALS I | $20,698,000 | -44.2% | 2,086,449 | -5.3% | 0.46% | -40.5% |
| BCRX | Sell | BIOCRYST PHARMACEUTICALS INC | $16,455,000 | -29.5% | 1,012,000 | -40.0% | 0.37% | -24.9% |
| Sell | XILIO THERAPEUTICS INC | $14,696,000 | -56.4% | 2,078,692 | -3.5% | 0.33% | -53.5% | |
| SWTX | Sell | SPRINGWORKS THERAPEUTICS INC | $14,109,000 | -49.6% | 249,988 | -44.7% | 0.32% | -46.4% |
| KALV | Sell | KALVISTA PHARMACEUTICALS INC | $12,241,000 | -21.3% | 830,472 | -29.3% | 0.27% | -16.0% |
| CGEM | Sell | CULLINAN ONCOLOGY INC | $3,932,000 | -62.1% | 375,585 | -44.1% | 0.09% | -59.4% |
| RYTM | Sell | RHYTHM PHARMACEUTICALS INC | $3,352,000 | -82.0% | 291,005 | -84.4% | 0.08% | -80.8% |
| AMWL | Sell | AMERICAN WELL CORPcl a | $1,647,000 | -72.5% | 391,115 | -60.5% | 0.04% | -70.6% |
| PMVP | Sell | PMV PHARMACEUTICALS INC | $10,000 | -99.9% | 470 | -99.9% | 0.00% | -100.0% |
| BDSI | Exit | BIODELIVERY SCIENCES INTL IN | $0 | – | -29,204 | -100.0% | -0.00% | – |
| WVE | Exit | WAVE LIFE SCIENCES LTD | $0 | – | -552,690 | -100.0% | -0.04% | – |
| Exit | PYXIS ONCOLOGY INC | $0 | – | -311,754 | -100.0% | -0.07% | – | |
| Exit | DEFINITIVE HEALTHCARE CORP | $0 | – | -250,000 | -100.0% | -0.14% | – | |
| Exit | HYPERFINE INC | $0 | – | -1,000,000 | -100.0% | -0.15% | – | |
| PRVA | Exit | PRIVIA HEALTH GROUP INC | $0 | – | -300,000 | -100.0% | -0.16% | – |
| Exit | GUARDANT HEALTH INCnote 11/1 | $0 | – | -8,000,000 | -100.0% | -0.17% | – | |
| Exit | WEAVE COMMUNICATIONS INC | $0 | – | -554,519 | -100.0% | -0.18% | – | |
| Exit | LIANBIOsponsored ads | $0 | – | -1,782,747 | -100.0% | -0.23% | – | |
| BPMC | Exit | BLUEPRINT MEDICINES CORP | $0 | – | -110,000 | -100.0% | -0.25% | – |
| SRPT | Exit | SAREPTA THERAPEUTICS INC | $0 | – | -141,000 | -100.0% | -0.27% | – |
| APLS | Exit | APELLIS PHARMACEUTICALS INC | $0 | – | -343,213 | -100.0% | -0.34% | – |
| BBIO | Exit | BRIDGEBIO PHARMA INCcall | $0 | – | -1,000,000 | -100.0% | -0.35% | – |
| NVRO | Exit | NEVRO CORP | $0 | – | -216,000 | -100.0% | -0.37% | – |
| FIGS | Exit | FIGS INCcl a | $0 | – | -829,707 | -100.0% | -0.48% | – |
| VIVO | Exit | MERIDIAN BIOSCIENCE INC | $0 | – | -1,125,083 | -100.0% | -0.48% | – |
| ESPR | Exit | ESPERION THERAPEUTICS INC NE | $0 | – | -5,000,000 | -100.0% | -0.52% | – |
| PCRX | Exit | PACIRA BIOSCIENCES INC | $0 | – | -596,338 | -100.0% | -0.75% | – |
| PTGX | Exit | PROTAGONIST THERAPEUTICS INC | $0 | – | -1,172,943 | -100.0% | -0.84% | – |
| APR | Exit | APRIA INC | $0 | – | -1,655,795 | -100.0% | -1.13% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-05-16
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AERIE PHARMACEUTICALS INC | 36 | Q3 2022 | 3.6% |
| CENTENE CORP DEL | 30 | Q3 2023 | 3.0% |
| BIOCRYST PHARMACEUTICALS INC | 29 | Q3 2023 | 2.2% |
| MOLINA HEALTHCARE INC | 26 | Q3 2022 | 1.7% |
| EHEALTH INC | 25 | Q3 2020 | 2.0% |
| INTERCEPT PHARMACEUTICALS IN | 24 | Q1 2023 | 2.2% |
| MYLAN NV | 23 | Q3 2020 | 6.2% |
| PORTOLA PHARMACEUTICALS INC | 23 | Q1 2019 | 6.0% |
| BROOKDALE SR LIVING INC | 23 | Q3 2023 | 2.2% |
| ALIMERA SCIENCES INC | 23 | Q3 2019 | 0.8% |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| DA32 Life Science Tech Acquisition Corp. | August 01, 2023 | 5,145,000 | 91.1% |
| CareMax, Inc. | March 13, 2023 | 18,691,423 | 16.4% |
| CareMax, Inc. | June 02, 2022 | 18,691,423 | 20.7% |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 3 | 2024-03-19 |
| 4 | 2024-03-19 |
| 4 | 2024-03-12 |
| 3 | 2024-03-08 |
| 4 | 2024-02-16 |
| 13F-HR | 2024-02-14 |
| 4 | 2024-02-08 |
| 3 | 2024-02-01 |
| 4 | 2023-11-21 |
| 13F-HR | 2023-11-14 |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.